title: Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients.
abstract: We determined the T-cell responses against botulinum neurotoxin type A (BoNT/A) and tetanus toxin (TeNT) of peripheral blood lymphocytes from 95 BoNT-treated patients and 63 non-treated control subjects. The patient group included 80 cervical dystonia and 15 other movement disorder cases. Positive T-cell responses to BoNT/A were detected in 70% of the treated patients, and in only 3% of controls. T-cell responses of BoNT-treated patients against BoNT/A did not differ between patients who were clinically responsive and those who had become non-responsive to the treatment. BoNT-treated patients gave significantly higher in vitro T-cell responses to TeNT than did the controls.
authors: Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
authors: Minako
authors: M
authors: Oshima
authors: Philip R
authors: PR
authors: Deitiker
authors: Joseph
authors: J
authors: Jankovic
authors: Drake D
authors: DD
authors: Duane
authors: K Roger
authors: KR
authors: Aoki
authors: M Zouhair
authors: MZ
authors: Atassi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000494:pharmacology* / Q000627:therapeutic use; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D009498:Neurotoxins / Q000494:pharmacology* / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013744:Tetanus Toxin / Q000494:pharmacology / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D009498:Neurotoxins; D013744:Tetanus Toxin; D019274:Botulinum Toxins, Type A